Minerva Neurosciences, Inc.(NERV)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $41.2M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
NERV Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Minerva Neurosciences, Inc. (NERV), a Healthcare sector company. NERV is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $41.2m in revenue and is scored on the micro-cap board instead. Top institutional holders of NERV by reported 13-F value include FEDERATED HERMES, Jupiter Topco, Vivo Capital, based on the most recent SEC filings. NERV trades on the Nasdaq exchange and files with the SEC under CIK 1598646. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NERV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Minerva Neurosciences, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$17.5M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
-20492.7% YoYOperating Income
+30.9% YoYEPS (Diluted)
-18347.4% YoYTotal Assets
+163.8% YoYOp. Cash Flow
+30.9% YoYFree Cash Flow
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | $0.00 -100.0% | $41.2M |
| Net Income | $-293.4M -20492.7% | $1.4M +104.8% | $-30.0M +6.6% | $-32.1M +35.7% | $-49.9M -2671.4% | $1.9M |
| Operating Income | $-15.1M +30.9% | $-21.8M +5.5% | $-23.1M +8.4% | $-25.2M +44.4% | $-45.4M -2556.5% | $1.8M |
| EPS (Diluted) | $-34.67 -18347.4% | $0.19 +104.1% | $-4.61 +23.3% | $-6.01 +35.7% | $-9.35 -18800.0% | $0.05 |
| Total Assets | $98.0M +163.8% | $37.1M -34.7% | $56.9M +3.3% | $55.1M -28.6% | $77.1M +33.8% | $57.6M |
| Operating Cash Flow | $-13.5M +30.9% | $-19.6M -32.2% | $-14.8M +40.0% | $-24.6M -0.2% | $-24.6M +27.3% | $-33.8M |
| Free Cash Flow | — | — | — | $-24.7M | — | — |
Get alerted when NERV's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Minerva Neurosciences, Inc. including:
Top Institutional Holders of NERV
FEDERATED HERMES, INC.
$25.9M4,670,426 shJupiter Topco LLC
$24.3M4,386,027 shVivo Capital, LLC
$24.0M4,322,747 shBALYASNY ASSET MANAGEMENT L.P.
$23.6M4,257,000 shLogos Global Management LP
$18.3M3,288,777 shFARALLON CAPITAL MANAGEMENT LLC
$13.1M2,365,000 shBlackRock, Inc.
$12.4M2,240,578 shAlly Bridge Group (NY) LLC
$12.1M2,175,802 shForesite Capital Management VI LLC
$11.0M1,985,584 shVANGUARD CAPITAL MANAGEMENT LLC
$10.5M1,892,807 sh
| Fund | Value | Shares |
|---|---|---|
| FEDERATED HERMES, INC. | $25.9M | 4,670,426 |
| Jupiter Topco LLC | $24.3M | 4,386,027 |
| Vivo Capital, LLC | $24.0M | 4,322,747 |
| BALYASNY ASSET MANAGEMENT L.P. | $23.6M | 4,257,000 |
| Logos Global Management LP | $18.3M | 3,288,777 |
| FARALLON CAPITAL MANAGEMENT LLC | $13.1M | 2,365,000 |
| BlackRock, Inc. | $12.4M | 2,240,578 |
| Ally Bridge Group (NY) LLC | $12.1M | 2,175,802 |
| Foresite Capital Management VI LLC | $11.0M | 1,985,584 |
| VANGUARD CAPITAL MANAGEMENT LLC | $10.5M | 1,892,807 |
More Healthcare Companies
View all Healthcare →Put NERV on your watchlist
Track score changes the day Minerva Neurosciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is NERV a good stock to buy?
13F Pro's AI-powered analysis of Minerva Neurosciences, Inc. (NERV) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NERV are available on the NERV stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. NERV is classified as a small company.
Which hedge funds own NERV?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NERV. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Minerva Neurosciences, Inc.'s investment landscape.